PRO-C20
A fragment of the C-terminal domain of type XX collagen, enabling non-invasive monitoring of extracellular matrix remodeling and tumor-associated fibrosis across multiple solid tumor types.
Key features and values
- Quantifies C-terminal fragments of type XX collagen associated with extracellular matrix remodeling.
- Reflects tumor-associated fibrosis in various solid tumors.
- Provides a non-invasive measure of extracellular matrix dynamics in oncology research.
- Supports monitoring of disease progression and response to therapies targeting tumor stroma.
- Applicable in research on cancers characterized by aberrant extracellular matrix turnover.
- Facilitates evaluation of interventions aimed at modulating extracellular matrix degradation in cancer.
- Complements other biomarkers for a comprehensive assessment of tumor microenvironment dynamics.
Description
The PRO-C20 biomarker assay measures specific fragments of the C-terminal domain of type XX collagen, serving as an indicator of extracellular matrix remodeling and tumor-associated fibrosis in various solid tumors. This non-invasive assay provides insights into tissue remodeling processes associated with cancer progression. By quantifying type XX collagen degradation products, the PRO-C20 assay aids in monitoring disease progression, evaluating treatment efficacy, and understanding the underlying mechanisms of tumor stroma remodeling. It serves as a valuable tool in research settings for assessing the dynamics of extracellular matrix turnover in oncology.
Nordic Bioscience’s assays and services are research use only products and services and do not qualify for medical or diagnostic purposes.
